Our Pipeline

Dragonfly's novel cytokines and TriNKET® NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.

Dragonfly’s pipeline is robust and continues to grow both internally and with BMS, Merck, AbbVie, and Gilead

DF1001 (HER2-targeting)         
Clinical trial ID: NCT04143711

TriNKET

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

logo-text_edited.png

Dragonfly Internal

Multiple candidates

TriNKET

logo-text_edited.png

DF6215

CYTOKINE

logo-text_edited.png

DF9001 (EGFR-targeting)

TriNKET

logo-text_edited.png

DF6002/BMS-985415 (IL-12-targeting)     
Clinical trial ID: NCT04423029

CYTOKINE

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

BristolMS-293x300.jpg

BMS + Dragonfly Partnered

DF4001 (licensed)

TriNKET

BristolMS-293x300.jpg

DF3001 (BCMA-targeting)
Clinical trial ID: NCT04975399 

TriNKET

BristolMS-293x300.jpg

DF2001 (CD33-targeting)   
Clinical trial ID: NCT04789655

TriNKET

BristolMS-293x300.jpg

DF5008 (licensed)

TriNKET

BristolMS-293x300.jpg

DF2200 (licensed)

TriNKET

BristolMS-293x300.jpg

Multiple candidates

TriNKET

BristolMS-293x300.jpg

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

Merck + Dragonfly Partnered

DF8001/MK4464 (licensed)

TriNKET

MERCK-logo.png

DF8101 (licensed)

TriNKET

MERCK-logo.png

Multiple candidates

TriNKET

MERCK-logo.png

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

AbbVie + Dragonfly Partnered

DF4101/ABBV-303 (licensed)

TriNKET

Abbvie-Logo-2_edited.png

Multiple candidates

TriNKET

Abbvie-Logo-2_edited.png

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

Gilead + Dragonfly Partnered

DF7001 (5T4-targeting - licensed)

TriNKET

Gilead_Logo_standard_RGB.png

Multiple candidates

TriNKET

Gilead_Logo_standard_RGB.png